The short version of Mod GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
=== Tracing food sources and diets === Different photosynthetic pathways preferentially select for the lighter 12C, but their selectivity differs. Grasses in temperate climates (barley, rice, wheat, rye, and oats, plus sunflower, potato, tomatoes, peanuts, cotton, sugar beet, and most trees and their nuts or fruits, roses, and Kentucky bluegrass) follow a C3 photosynthetic pathway that will yield δ13C values averaging about −26.5‰. Grasses in hot arid climates (maize in particular, but also millet, sorghum, sugar cane, and crabgrass) follow a C4 photosynthetic pathway that produces δ13C values averaging about −12.5‰. It follows that eating these different plants will affect the δ13C values in the consumer's body tissues. If an animal (or human) eats only C3 plants, their δ13C values will be from −18.5 to −22.0‰ in their bone collagen and −14.5‰ in the hydroxylapatite of their teeth and bones. In contrast, C4 feeders will have bone collagen with a value of −7.5‰ and hydroxylapatite value of −0.5‰. In case studies, millet and maize eaters can easily be distinguished from rice and wheat eaters. Studying how these dietary preferences are distributed geographically through time can illuminate migration paths of people and dispersal paths of different agricultural crops. However, human groups have often mixed C3 and C4 plants (historically, northern Chinese subsisted on wheat (C3) and millet (C4)) or mixed plant and animal groups (for example, southeastern Chinese subsisting on rice and fish).
=== Off-label drugs === Acetazolamide (Diamox) – carbonic anhydrase inhibitor Atomoxetine (Strattera) – norepinephrine reuptake inhibitor (NRI) Eszopiclone (Lunesta) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/Z-drug Oxybutynin (Ditropan) – muscarinic acetylcholine receptor antagonist (anticholinergic) Pimavanserin (Nuplaizid) – serotonin 5-HT2A receptor antagonist Sodium oxybate (GHB; Xyrem) – GABAB receptor agonist and GHB receptor agonist Trazodone (Desyrel) – various actions Weight-loss drugs (e.g., liraglutide, semaglutide) – obesity-related sleep apnea
=== 2010-2013 === In 2010, Janusz Bugajski argued that Vladimir Putin and Dmitry Medvedev "were convinced that Europe and the United States needed Russia much more than Russia needed the West and calculated that several tangible advantages would be gained from the military attack on Georgia". In 2011, Michael Cecire explained that "citations of ’US training’ to Georgian troops have limited relevance in the context of the August war" since Americans trained Georgians for fighting with the insurgents and not for the war with Russia. Cecire further states: "The absence of Georgia's best troops has also been cited as being one of the clearest signs that Tbilisi did not have a premeditated intention to get into a war, and certainly not one with the Russian military. [...] Many observers agree that even if Georgia did premeditate the August 2008 war (and that is a big if), it was not counting on Russian involvement". In 2011, Dr. Ariel Cohen and Colonel Robert E. Hamilton wrote, "The Vladimir Putin-Dmitry Medvedev administration and the defense establishment formulated far-reaching goals when they carefully prepared over 2 1/2 years for a combined operations-style invasion of Georgia.
In a broad way, it usually includes a test of ruggedness among inter-collaborators, or a test of robustness within an organization However, the U.S. Food and Drug Administration (FDA) has specifically defined it for its administration, as "System suitability testing is an integral part of many analytical procedures. The tests are based on the concept that the equipment, electronics, analytical operations and samples to be analyzed constitute an integral system that can be evaluated as such. System suitability test parameters to be established for a particular procedure depend on the type of procedure being validated". In some cases of analytical chemistry, a system suitability test could be rather a method specific than universal. Such examples are chromatographic analysis, which is usually media (column, paper or mobile solvent) sensitive However to the date of this writing, this kind of approaches are limited to some of pharmaceutical compendial methods, by which the detecting of impurities, or the quality of the intest analyzed are critical (i.e., life and death). This is probably largely due to:
Dipeptides are white solids. Many are far more water-soluble than the parent amino acids. For example, the dipeptide Ala-Gln has the solubility of 586 g/L more than 10x the solubility of Gln (35 g/L). Dipeptides also can exhibit different stabilities, e.g. with respect to hydrolysis. Gln does not withstand sterilization procedures, whereas this dipeptide does. Because dipeptides are prone to hydrolysis, the high solubility is exploited in infusions, i.e. to provide nutrition.
Sources: en.wikipedia.org
== History == SR-17018 was patented in 2016 and first described in the scientific literature by Laura Bohn and colleagues at the Scripps Research Institute in Jupiter, Florida in 2017. The drug was encountered as a novel designer drug online by 2023. Analogues like brorphine and SR-14968 have also been encountered as novel designer drugs. Brorphine is said to not be popular among recreational users as it produces little euphoria but reportedly still has potential for severe respiratory depression. In 2024, discussion of SR-17018 on the social media website Reddit suddenly dramatically increased and the drug emerged as an informal treatment for opioid discontinuation and withdrawal. On July 1, 2026, the United States Drug Enforcement Administration (DEA) signed a letter of intent to temporarily place SR-17018 under Schedule I of the Controlled Substances Act. This will likely take effect on July 31, 2026. There has been opposition to the announcement, for instance by the Students for Sensible Drug Policy (SSDP).
Because prokaryotic mRNA does not need to be processed or transported, translation by the ribosome can begin immediately after the end of transcription. Therefore, it can be said that prokaryotic translation is coupled to transcription and occurs co-transcriptionally. In eukaryotic cells the process of translation starts with the information stored in the nucleotide sequence of DNA. This is first transformed into mRNA, then transfer RNA (tRNA) specifies which three-nucleotide codon from the genetic code corresponds to which amino acid. Eukaryotic mRNA that has been processed and transported to the cytoplasm (i.e., mature mRNA) can then be translated by ribosomes. Translation may occur at ribosomes free in the cytoplasm, or targeted to the endoplasmic reticulum by the signal recognition particle. Therefore, unlike in prokaryotes, eukaryotic translation is not directly coupled to transcription. In some contexts, protein abundance can increase even when mRNA abundance decreases, because translation efficiency and protein turnover are regulated independently of transcript levels; this has been reported for mRNA and protein levels of EEF1A1 in breast cancer.
Whether food can be addictive is disputed. Neither the DSM-5-TR nor the ICD-11 recognizes a food or eating addiction, and researchers disagree about whether the concept is best framed as an addiction to specific foods, a pattern of disordered eating, or neither. Proponents argue that ultra-processed foods high in refined carbohydrate and fat meet the criteria conventionally used to identify an addictive substance, because processing delivers these nutrients faster and in higher concentrations than they occur in nature. Critics respond that no single constituent has been isolated as the addictive agent, unlike the case for a drug. Most research uses the Yale Food Addiction Scale, which applies the DSM-5 criteria for substance use disorder to eating. Food addiction as measured this way overlaps with, but is not the same as, binge eating disorder: not everyone with an eating disorder screens positive, and not everyone screening positive has a diagnosed eating disorder.
Alanine (symbol Ala or A), or α-alanine, is an α-amino acid that is used in the biosynthesis of proteins. It contains an amine group and a carboxylic acid group, both attached to the central carbon atom which also carries a methyl group side chain. Consequently it is classified as a non-polar, aliphatic α-amino acid. Under biological conditions, alanine exists in its zwitterionic form with its amine group protonated (as −NH+3) and its carboxyl group deprotonated (as −CO−2). Alanine is encoded by all codons starting with GC (GCU, GCC, GCA, and GCG). The L-isomer of alanine (left-handed) is the one that is incorporated into proteins. L-alanine is second only to L-leucine in rate of occurrence, accounting for 7.8% of the primary structure in a sample of 1,150 proteins. The right-handed form, D-alanine, occurs in peptides in some bacterial cell walls (in peptidoglycan) and in some peptide antibiotics, and occurs in the tissues of many crustaceans and molluscs as an osmolyte. Alanine is not an essential amino acid in humans because it can be synthesized metabolically and does not need to be present in the diet. However hypoalaninemia (alanine deficiency) is possible under certain conditions such as ketotic hypoglycemia.
== Epidemiology == A study from the Netherlands has shown an incidence of 1 in 20 million births. According to the Progeria Research Foundation, as of September 2020, there are 179 known cases in the world, in 53 countries; 18 of the cases were identified in the United States. Hundreds of cases have been reported in medical history since 1886. However, the Progeria Research Foundation believes there may be as many as 150 undiagnosed cases worldwide. There have been only two cases in which a healthy person was known to carry the LMNA mutation that causes progeria. One family from India had four of six children with progeria.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.